EA201791701A1 - Диспергируемые композиции - Google Patents

Диспергируемые композиции

Info

Publication number
EA201791701A1
EA201791701A1 EA201791701A EA201791701A EA201791701A1 EA 201791701 A1 EA201791701 A1 EA 201791701A1 EA 201791701 A EA201791701 A EA 201791701A EA 201791701 A EA201791701 A EA 201791701A EA 201791701 A1 EA201791701 A1 EA 201791701A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
dispensable compositions
dispensable
tuberculosis
elderly
Prior art date
Application number
EA201791701A
Other languages
English (en)
Inventor
Маниш Кумар Гупта
Шрипад Васудео Маратхе
Каустубх Рамеш Тамбвекар
Шридеви Велаюдхан Наир
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201791701A1 publication Critical patent/EA201791701A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Lubricants (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к диспергируемым композициям, содержащим бедаквилина фумарат в качестве активного ингредиента. Такие композиции являются применимыми в лечении туберкулеза, а присущие им свойства диспергируемости обеспечивают им применимость, в частности, среди популяции детского или пожилого возраста.
EA201791701A 2015-01-27 2016-01-26 Диспергируемые композиции EA201791701A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN264MU2015 2015-01-27
PCT/EP2016/051545 WO2016120258A1 (en) 2015-01-27 2016-01-26 Dispersible compositions

Publications (1)

Publication Number Publication Date
EA201791701A1 true EA201791701A1 (ru) 2017-11-30

Family

ID=55229712

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791701A EA201791701A1 (ru) 2015-01-27 2016-01-26 Диспергируемые композиции

Country Status (29)

Country Link
US (2) US20180000810A1 (ru)
EP (1) EP3250182B1 (ru)
JP (3) JP7291458B2 (ru)
KR (1) KR102631986B1 (ru)
CN (2) CN114129526A (ru)
AU (2) AU2016212116B2 (ru)
CA (1) CA2973301A1 (ru)
CY (1) CY1126107T1 (ru)
DK (1) DK3250182T3 (ru)
EA (1) EA201791701A1 (ru)
ES (1) ES2948805T3 (ru)
FI (1) FI3250182T3 (ru)
HK (1) HK1243644A1 (ru)
HR (1) HRP20230616T1 (ru)
HU (1) HUE062481T2 (ru)
IL (2) IL310920A (ru)
LT (1) LT3250182T (ru)
MA (1) MA41411B1 (ru)
MD (1) MD3250182T2 (ru)
MX (1) MX2017009681A (ru)
PE (1) PE20171319A1 (ru)
PH (1) PH12017501331A1 (ru)
PL (1) PL3250182T3 (ru)
PT (1) PT3250182T (ru)
RS (1) RS64308B1 (ru)
SG (1) SG11201705944TA (ru)
SI (1) SI3250182T1 (ru)
UA (1) UA126891C2 (ru)
WO (1) WO2016120258A1 (ru)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2937365C (en) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same
WO2019012100A1 (en) * 2017-07-14 2019-01-17 Janssen Pharmaceutica Nv EXTENDED ACTION FORMULATIONS
WO2019193609A1 (en) * 2018-04-05 2019-10-10 Cipla Limited Pharmaceutical formulations
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
US20220023282A1 (en) * 2018-12-13 2022-01-27 Mannkind Corporation Compositions of Bedaquiline, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
JP2022516671A (ja) * 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2021257461A1 (en) * 2020-06-15 2021-12-23 Mylan Laboratories Limited Combination antibacterial composition and method for antibacterial therapy
CN111888477B (zh) * 2020-09-15 2023-03-07 北京福元医药股份有限公司 一种贝达喹啉药物制剂
KR102478006B1 (ko) 2020-12-03 2022-12-15 정승찬 자동차 긴급 제동장치
US11793808B2 (en) 2021-02-22 2023-10-24 Mannkind Corp. Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
GB202211231D0 (en) 2022-08-02 2022-09-14 Glaxosmithkline Ip No 2 Ltd Novel formulation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je
EP1753427B1 (en) 2004-05-28 2008-04-02 Janssen Pharmaceutica N.V. Use of substituted quinoline derivatives for the treatment of drug resistant mycobacterial diseases
EE05394B1 (et) 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP5410749B2 (ja) * 2005-05-25 2014-02-05 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ （アルファｓ，ベータｒ）−６−ブロモ−アルファ−［２−（ジメチルアミノ）エチル］−２−メトキシ−アルファ−１−ナフタレニル−ベータ−フェニル−３−キノリンエタノールの製造方法
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
UA97813C2 (ru) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
EP2271320A4 (en) * 2008-04-02 2011-05-18 Reddys Lab Ltd Dr PHARMACEUTICAL RALOXIFY FORMULATIONS
CA2735229C (en) * 2008-09-03 2014-01-28 Pfizer Inc. Combination therapy for tuberculosis
US20120207838A1 (en) * 2011-02-10 2012-08-16 Perricone Nicholas V Treatment of Psoriasis Using Oral Dosage Forms of Nitrone Spin Traps
WO2013153162A1 (en) * 2012-04-11 2013-10-17 Sandoz Ag Polymorph of rilpivirine hydrochloride
US20140075692A1 (en) * 2012-09-18 2014-03-20 Unger Marketing International, Llc. Multiuse cleaning tool handle
JP2015537013A (ja) * 2012-11-19 2015-12-24 アサンタ・アー／エス 速崩性錠剤

Also Published As

Publication number Publication date
LT3250182T (lt) 2023-07-10
WO2016120258A1 (en) 2016-08-04
FI3250182T3 (fi) 2023-06-28
IL310920A (en) 2024-04-01
PL3250182T3 (pl) 2023-07-31
RS64308B1 (sr) 2023-07-31
MX2017009681A (es) 2017-10-18
JP7291458B2 (ja) 2023-06-15
SI3250182T1 (sl) 2023-08-31
BR112017015784A2 (pt) 2018-03-27
IL253626B1 (en) 2024-04-01
MD3250182T2 (ro) 2023-09-30
HUE062481T2 (hu) 2023-11-28
HRP20230616T1 (hr) 2023-09-29
SG11201705944TA (en) 2017-08-30
EP3250182A1 (en) 2017-12-06
PE20171319A1 (es) 2017-09-07
AU2021204135B2 (en) 2023-10-05
CN107205945A (zh) 2017-09-26
IL253626A0 (en) 2017-09-28
JP2018502928A (ja) 2018-02-01
JP2022176982A (ja) 2022-11-30
US20180000810A1 (en) 2018-01-04
AU2021204135A1 (en) 2021-07-15
AU2016212116B2 (en) 2021-07-15
MA41411B1 (fr) 2023-07-31
ES2948805T3 (es) 2023-09-19
MA41411A (fr) 2017-12-05
HK1243644A1 (zh) 2018-07-20
CN114129526A (zh) 2022-03-04
CA2973301A1 (en) 2016-08-04
DK3250182T3 (da) 2023-06-26
CY1126107T1 (el) 2023-11-15
AU2016212116A1 (en) 2017-07-27
EP3250182B1 (en) 2023-04-26
KR20170106447A (ko) 2017-09-20
UA126891C2 (uk) 2023-02-22
JP2021098706A (ja) 2021-07-01
US20220331307A1 (en) 2022-10-20
KR102631986B1 (ko) 2024-01-30
PH12017501331A1 (en) 2017-12-11
PT3250182T (pt) 2023-07-07

Similar Documents

Publication Publication Date Title
EA201791701A1 (ru) Диспергируемые композиции
EA201990043A1 (ru) Антибактериальные соединения
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
EA201890204A1 (ru) Антибактериальные соединения
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
NZ733174A (en) Quinazoline derivatives used to treat hiv
PH12015501648A1 (en) 2-aminopyrimidine derivatives for the treatment of viral infections
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX360041B (es) Composiciones y metodos para el cuidado personal.
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
UY34617A (es) Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas
ZA201805792B (en) Taurine and aloe synergistic anti-irritant compositions and methods
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
CY1123366T1 (el) Παραγωγα 8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δeκανιου
MX2020001885A (es) Formulaciones de daptomicina.
MX2019011613A (es) Formulaciones de acido 1-amino-1-ciclopropanocarboxilico.
MX362155B (es) Combinaciones de alquilamidotiazoles y sustancias aromaticas.
MY178960A (en) Hiv treatment formulation of atazanavir and cobicistat
MX2020005056A (es) Emulsiones para el tratamiento tópico de infecciones dérmicas y de mucosas.
MX2018010264A (es) Formulaciones libres de solventes de sustancias activas de bajo punto de fusion.
MX2020001632A (es) Composiciones que comprenden cepas bacterianas.
MX2015001648A (es) Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos.
MX2014011218A (es) Uso de agentes tensoactivos anfotericos para la prevencion y tratamiento de biopeliculas vaginales patogenas en infecciones vaginales.
MX2020005682A (es) Extracto de helichrysum gymnocephalum para el tratamiento y/o la prevencion de dermatosis inflamatorias.
MX2015014657A (es) Nuevos agentes antibacterianos de fenicol.